London open: Oil stocks lift Footsie
1st Oct 2010 09:13
Shares have got off to a strong start on the first day of the last quarter, with oil stocks setting the pace. BP is higher amid speculation that dividends will soon be resumed. Bob Dudley, who becomes chief executive of the oil company today, said that the board would meet soon to discuss restoring
Read moreLondon pre-open: BP divi hopes to lift Footsie
1st Oct 2010 07:37
London looks set to start the final quarter of 2010 in positive mood with sentiment lifted by hints from the incoming boss of oil giant BP that the company is ready to restore dividend payments that were suspended during the Gulf of Mexico crisis. Bob Dudley, who becomes chief executive of the oil
Read moreHikma shrugs off drug ban threat
1st Oct 2010 07:10
Drugs group Hikma Pharmaceuticals has moved to calm fears about the impact of a plan by US regulators to ban unapproved oral colchicine products to treat gout. Its shares tumbled yesterday on the news. Investors also worried about comments from Numis analyst Jonathan Kwok that August's impressive i
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
6th Jul 2010 08:17
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0717 GMT [Dow Jones] JPMorgan Cazenove initiates Hikma Pharmaceuticals (HIK.LN) at overweight with 870p target, citing lea
Read moreMARKET TALK: JPMorgan Starts Hikma At Overweight
6th Jul 2010 08:17
0717 GMT [Dow Jones] JPMorgan Cazenove initiates Hikma Pharmaceuticals (HIK.LN) at overweight with 870p target, citing leading long-term growth and the potential for a near-term EPS beat. Notes Hikma's competitive advantages as the top local player in the Middle East & North Africa pharmaceutical ma
Read moreMARKET TALK: Royal Bank of Scotland Starts Hikma Pharma At Hold
6th Jul 2010 07:53
0653 GMT [Dow Jones] Royal Bank of Scotland initiates coverage on Hikma Pharmaceuticals (HIK.LN), with a hold rating and 750p target price. "Our optimistic forecasts reflect Hikma's strong position in MENA [Middle East and North Africa] and its strategy of globalizing the platform, which should allo
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
6th Jul 2010 07:53
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0653 GMT [Dow Jones] Royal Bank of Scotland initiates coverage on Hikma Pharmaceuticals (HIK.LN), with a hold rating and 750p
Read moreMARKET TALK: UBS Raises Hikma Price Target
23rd Jun 2010 09:16
0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rates and a slightly higher interest charge than previously anticipated. Notes Hikma has launched oncology injectable products in the Middle East and North Africa, and says this is
Read moreUK MARKET TALK ROUNDUP: SHARES GAINING
23rd Jun 2010 09:16
Stocks on the rise in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0816 GMT [Dow Jones] UBS raises Hikma Pharmaceuticals (HIK.LN) price target to 770p from 715p to adjust for current FX rat
Read moreMARKET TALK: Morgan Stanley Downgrades Hikma To Equalweight
18th Jun 2010 07:33
0633 GMT [Dow Jones] Morgan Stanley downgrades Hikma Pharmaceuticals (HIK.LN) to equalweight from overweight but raises price target to 750p from 700p. The bank says a Middle East and North Africa site visit confirmed fundamentals, but MS says the scope for upgrades is limited and the potential risk
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
18th Jun 2010 07:33
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0633 GMT [Dow Jones] Morgan Stanley downgrades Hikma Pharmaceuticals (HIK.LN) to equalweight from overweight but raises price
Read moreHikma maintains guidance
13th May 2010 14:52
Pharmaceutical firm Hikma has maintained its guidance for 2010 revenue growth in the low teens, with gross margin broadly in line with 2009. The group said it continues to expect Branded sales growth in the low double digits for the full year due to the disruption in the Algerian market in the begi
Read moreEnQuest non-exec makes second purchase
23rd Apr 2010 16:24
North Sea oil and gas explorer and producer EnQuest is one of the best performers in the FTSE 250 index on the back of buying by non-executive director Alexandre Schneiter. EnQuest was demerged from oil services provider Petrofac on 6 April. Petrofac stayed in the FTSE 100 index but EnQuest fell o
Read moreHikma takes full control of Algerian JV
12th Apr 2010 09:24
Hikma Pharmaceuticals is to take full ownership of the Algerian company Al Dar Al Arabia Pharmaceutical Manufacturing. Jordan-based pharmaceutical company Hikma is paying $18.5m for Dar Al Dawa's 50% stake in the joint venture. Al Dar Al Arabia owns a recently built 6,000 square metre manufacturin
Read moreBentley sells majority of Sports Direct stake
9th Apr 2010 16:47
Simon Bentley, a non-executive director in Mike Ashley's Sports Direct International, has sold four-fifths of his shareholding. Bentley raised £213,000 from selling 200,000 shares at 106.55p each. That leaves Bentley with 50,000 shares in the sports goods retailer. Bentley is a former chairman o
Read more